RxDoctor Payments Data

David Santellan, NP

Nurse Practitioner · Placerville, CANPI 1245903558

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 61 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$363
  • AstraZeneca$208
  • GSK$176
  • Lilly USA, LLC$160
  • Novo Nordisk$160
  • Pfizer$75
  • plus $243 from 7 others

What the payments were for

  • Food & beverage$1,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,383 in reported general payments places this provider in the 80th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$34,830
Medicare patients
233
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$82,383
EliquisApixaban72$82,189
OzempicSemaglutide53$60,539
JanuviaSitagliptin Phosphate24$27,898
TrulicityDulaglutide23$21,884
MounjaroTirzepatide19$18,974
SymbicortBudesonide/Formoterol Fumarate35$12,978
RybelsusSemaglutide11$11,589
MyrbetriqMirabegron12$8,764
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$8,558
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$6,245
Atorvastatin Calcium681$5,356
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$4,759
Levothyroxine Sodium359$4,209
Rosuvastatin Calcium215$3,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$82,18972 claims
Novo NordiskOzempic, Rybelsus$160$72,12864 claims
Lilly USA, LLCTrulicity, Mounjaro$160$40,85942 claims
AstraZenecaSymbicort$208$12,97835 claims
AbbVieSynthroid$22$1,85837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Placerville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →